Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Kenneth Kenji Tanabe, M.D.

Co-Author

This page shows the publications co-authored by Kenneth Tanabe and Cristina Ferrone.
Connection Strength

2.408
  1. Hepatectomy for Solitary Hepatocellular Carcinoma: Resection Margin Width Does Not Predict Survival. J Gastrointest Surg. 2021 07; 25(7):1727-1735.
    View in: PubMed
    Score: 0.222
  2. Platelet and neutrophil to lymphocyte ratios predict survival in patients with resectable colorectal liver metastases. Am J Surg. 2020 12; 220(6):1579-1585.
    View in: PubMed
    Score: 0.218
  3. Management implications of fluorodeoxyglucose positron emission tomography/magnetic resonance in untreated intrahepatic cholangiocarcinoma. Eur J Nucl Med Mol Imaging. 2020 07; 47(8):1871-1884.
    View in: PubMed
    Score: 0.211
  4. Hepatocellular Carcinoma in Transplantable Child-Pugh A Cirrhotics: Should Cost Affect Resection vs Transplantation? J Gastrointest Surg. 2019 06; 23(6):1135-1142.
    View in: PubMed
    Score: 0.195
  5. Prognostic Significance of Surgical Margin Size After Neoadjuvant FOLFOX and/or FOLFIRI for Colorectal Liver Metastases. J Gastrointest Surg. 2017 Nov; 21(11):1831-1840.
    View in: PubMed
    Score: 0.181
  6. PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma. Clin Cancer Res. 2016 Jan 15; 22(2):470-8.
    View in: PubMed
    Score: 0.158
  7. Gallbladder lesions identified on ultrasound. Lessons from the last 10 years. J Gastrointest Surg. 2012 Mar; 16(3):549-53.
    View in: PubMed
    Score: 0.121
  8. Trends in presentation and survival for gallbladder cancer during a period of more than 4 decades: a single-institution experience. Arch Surg. 2009 May; 144(5):441-7; discussion 447.
    View in: PubMed
    Score: 0.102
  9. Positron Emission Tomography/Magnetic Resonance Imaging Versus the Standard of Care Imaging in the Diagnosis of Peritoneal Carcinomatosis. Ann Surg. 2022 Feb 17.
    View in: PubMed
    Score: 0.062
  10. Open hepatic resection in the elderly at two tertiary referral centers. Am J Surg. 2021 Sep; 222(3):594-598.
    View in: PubMed
    Score: 0.057
  11. Size of the Largest Colorectal Liver Metastasis Is an Independent Prognostic Factor in the Neoadjuvant Setting. J Surg Res. 2021 03; 259:253-260.
    View in: PubMed
    Score: 0.056
  12. Patterns of Failure and the Need for Biliary Intervention in Resected Biliary Tract Cancers After Chemoradiation. Ann Surg Oncol. 2020 Dec; 27(13):5161-5172.
    View in: PubMed
    Score: 0.055
  13. Fibrotic Response to Neoadjuvant Therapy Predicts Survival in Pancreatic Cancer and Is Measurable with Collagen-Targeted Molecular MRI. Clin Cancer Res. 2020 09 15; 26(18):5007-5018.
    View in: PubMed
    Score: 0.055
  14. Socioeconomic determinants of the surgical treatment of colorectal liver metastases. Am J Surg. 2020 10; 220(4):952-957.
    View in: PubMed
    Score: 0.054
  15. Palliative External Beam Radiation Therapy for Hepatocellular Carcinoma With Right Atrial Tumor Thrombus. Pract Radiat Oncol. 2020 May - Jun; 10(3):e183-e187.
    View in: PubMed
    Score: 0.053
  16. Hypofractionated Radiation Therapy for Unresectable/Locally Recurrent Intrahepatic Cholangiocarcinoma. Ann Surg Oncol. 2020 Apr; 27(4):1122-1129.
    View in: PubMed
    Score: 0.053
  17. Facility Type is Associated with Margin Status and Overall Survival of Patients with Resected Intrahepatic Cholangiocarcinoma. Ann Surg Oncol. 2019 Nov; 26(12):4091-4099.
    View in: PubMed
    Score: 0.052
  18. TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma. Cancer Discov. 2019 08; 9(8):1064-1079.
    View in: PubMed
    Score: 0.051
  19. Predictors of adjuvant treatment and survival in patients with intrahepatic cholangiocarcinoma who undergo resection. Am J Surg. 2019 11; 218(5):959-966.
    View in: PubMed
    Score: 0.050
  20. Protons versus Photons for Unresectable Hepatocellular Carcinoma: Liver Decompensation and Overall Survival. Int J Radiat Oncol Biol Phys. 2019 09 01; 105(1):64-72.
    View in: PubMed
    Score: 0.050
  21. Surgical resection versus ablation for early-stage hepatocellular carcinoma: A retrospective cohort analysis. Am J Surg. 2019 07; 218(1):157-163.
    View in: PubMed
    Score: 0.050
  22. Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy. Dis Model Mech. 2018 07 30; 11(7).
    View in: PubMed
    Score: 0.048
  23. Liver reirradiation for patients with hepatocellular carcinoma and liver metastasis. Pract Radiat Oncol. 2018 Nov - Dec; 8(6):414-421.
    View in: PubMed
    Score: 0.047
  24. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype. J Natl Cancer Inst. 2017 09 01; 109(9).
    View in: PubMed
    Score: 0.045
  25. A novel chemoradiation targeting stem and nonstem pancreatic cancer cells by repurposing disulfiram. Cancer Lett. 2017 11 28; 409:9-19.
    View in: PubMed
    Score: 0.045
  26. Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. J Clin Oncol. 2016 Feb 10; 34(5):460-8.
    View in: PubMed
    Score: 0.040
  27. Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma. Oncologist. 2015 Sep; 20(9):1019-27.
    View in: PubMed
    Score: 0.039
  28. Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma. Clin Cancer Res. 2014 Apr 01; 20(7):1884-90.
    View in: PubMed
    Score: 0.035
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.